Aciclovir gel - Sakai/SkyePharma
Alternative Names: Acyclovir gel - Sakai/SkyePharmaLatest Information Update: 02 Oct 2021
At a glance
- Originator Bioglan AB
- Class Antivirals; Eye disorder therapies; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Herpes simplex virus infections; Varicella zoster virus infections
Most Recent Events
- 04 Nov 2002 Aciclovir gel is now being developed by SkyePharma
- 31 May 2002 Bioglan's intellectual property rights to three topical drug delivery technologies, including ES-GEL™, have been acquired by SkyePharma
- 18 Feb 2000 Preclinical development for Herpes simplex virus infections in United Kingdom (Topical)